Hemophilia Spin Off (Details Textual) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Feb. 01, 2017
Assets and Liabilities Distributed to Bioverativ [Line Items]
Other	$ 48.8		$ 98.6	$ 180.4	$ 265.5
Cost of sales	370.0		416.9	1,120.8	1,100.2
Product, net	2,622.5		2,539.6	7,642.3	7,315.0
Hemophilia products
Assets and Liabilities Distributed to Bioverativ [Line Items]
Product, net			$ 217.0	74.4	$ 604.7
Bioverativ
Assets and Liabilities Distributed to Bioverativ [Line Items]
Term of Bioverativ transaction services agreement		12 months
Term of Bioverativ manufacturing and supply agreement		5 years
Cash						$ 302.7
Other	5.0			12.1
Cost of sales	$ 4.5			$ 11.1